<DOC>
	<DOCNO>NCT01482221</DOCNO>
	<brief_summary>The purpose study assess effect safety AZD6765 patient major depressive disorder exhibit inadequate response antidepressant . AZD6765 channel blocker NMDA class glutamate receptor .</brief_summary>
	<brief_title>A Study Assess Effect Safety AZD6765 Patients With Major Depressive Disorder</brief_title>
	<detailed_description>A Multicenter , Randomized , Double-blind , Parallel Group , Placebo-controlled , Phase IIb Efficacy Safety Study Adjunctive AZD6765 Patients Major Depressive Disorder ( MDD ) History Inadequate Response Antidepressants</detailed_description>
	<mesh_term>Disease</mesh_term>
	<mesh_term>Depressive Disorder</mesh_term>
	<mesh_term>Depression</mesh_term>
	<mesh_term>Depressive Disorder , Major</mesh_term>
	<mesh_term>Antidepressive Agents</mesh_term>
	<criteria>Provision sign date informed consent initiation studyrelated procedure . Male female patient age 18 70 year , inclusive . The patient must clinical diagnosis major depressive disorder lifetime history inadequate response least 3 antidepressant . Women childbearing potential must negative serum pregnancy test confirm use highly effective form birth control enrollment minimum 3 month study start . Outpatient status screen randomization visit . Patients history diagnose bipolar disorder schizophrenia schizoaffective disorder currently exhibit psychotic feature associate depression ; dementia suspicion thereof . Patients suicide attempt within last 6 month . Electroconvulsive therapy ( ECT ) , vagal nerve stimulation ( VNS ) transcranial magnetic stimulation ( TMS ) previous treatment ketamine infusion within 6 month prior screen , history deep brain stimulation . Patients history seizure disorder ( except febrile seizure childhood ) . Pregnancy lactation .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>September 2013</verification_date>
	<keyword>Major Depressive Disorder</keyword>
	<keyword>MDD</keyword>
	<keyword>Inadequate Response Antidepressant Therapy</keyword>
	<keyword>Channel blocker NMDA class glutamate receptor</keyword>
</DOC>